Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

Healy, David; Bahrick, Audrey S.; Bak, Maarten; Barbato, Angelo; Calabrò, Rocco Salvatore; Chubak, Barbara; Cosci, Fiammetta; Csóka, Antonei B.; D’Avanzo, Barbara; Diviccaro, Silvia; Giatti, Silvia; Goldstein, Irwin; Graf, Heiko; Irwig, Michael S.; Jannini, Emmanuele A.; Janssen, Paddy K.C.; Khera, Mohit; Kumar, Manish; Noury, Joanna Le; Lew–Starowicz, Michał; Linden, David; Lüning, Celine; Mangin, Dee; Melcangi, Roberto Cosimo; Rodríguez, Omar; Panicker, Jalesh N.; Patacchini, Arianna; Pearlman, Amy; Pukall, Caroline F.; Raj, S. John Michael; Reisman, Yacov; Rubin, Rachel; Schreiber, Rudy; Shipko, Stuart; Vašečková, Barbora; Waraich, Ahad

doi:10.3233/jrs-210023

Cited by 25 publications

(21 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This real-life retrospective study describes a small series of patients diagnosed with PSSD according to the recently published selection criteria and treated with a new multimodal approach, consisting of system sexology and bio-psycho-social interventions (Fig. 1) [18]. Consistent with evidence from the literature, we did not find any peripheral hormonal abnormalities which requested treatment [17,38].…”

Section: Discussionsupporting

confidence: 81%

“…All patients that met the following inclusion criteria were included: age between 18 and 60 years old, no pre-SSRI treatment sexual dysfunction, treatment-emergent sexual dysfunction while taking one antidepressant of the SSRI or and serotonin and norepinephrine reuptake inhibitor (SNRI) class, the antidepressant was discontinued at least 1 month before interview, sexual dysfunction per-sisted despite drug discontinuation, medical conditions and current medication use not associated with known sexual dysfunction, no report of addictive substances use. Only patients with high probability of PSSD according to previous published criteria have been selected [4,18].…”

Section: Subjectsmentioning

confidence: 99%

“…A new consensus on enduring sexual dysfunction following treatment with antidepressants, finasteride and isotretinoin has finally set the diagnostic criteria of such disorder. PSSD, besides featuring genital anesthesia, ejaculatory and orgasm dysfunction, and decreased libido, is a condition that must be present for at least 3 months, with no current medical condition accounting for the symptoms [18]. Since PSSD has only recently been codified as a stand-alone condition, there are no well-designed clinical trials and, therefore, a clear consensus on treatment modalities has not been reached so far.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunctions(PSSD): Clinical Experience with a Multimodal Approach

Reisman¹,

Jannini²,

Jannini³

2022

JOMH

Self Cite

View full text Add to dashboard Cite

Background: Post-SSRI sexual dysfunction (PSSD) is a set of heterogeneous sexual disorders, that may arise during the administration of antidepressant Selective Serotonin Reuptake Inhibitors (SSRIs) and serotonin and norepinephrine reuptake inhibitor (SNRIs) and may persist after their discontinuation. PSSD is commonly associated with sexual problems with marked distress and poor quality of life. To date, however, no effective treatment is available. The study describes the clinical experience with a newly introduced systems sexology approach involving bio-psycho-social interventions. Methods: In this study we retrospectively analyzed (from July 2019 to July 2020) twelve PSSD male patients (mean age 31.3 ± 6.21 years old) treated according to a recently introduced approach involving system sexology and bio-psycho-social interventions. The protocol was based on a combination of lifestyle changes, nutritional supplementation, pharmacological and behavioral interventions. Results: 12 patients with high probability of PSSD were selected. Patients reported a significant improvement in all International Index of Erectile Function-15 (IIEF) domains and Orgasmometer scores from the baseline at 6 months of follow-up. Conclusions: This study described for the first time a feasible and handy treatment procedure for PSSD, framework to improve patients complains, sexual function and satisfaction, and quality of life. Future randomized, placebo-controlled clinical studies with bigger cohorts will be needed in order to better assess this efficacy and confirm our results.

show abstract

Section: Discussionsupporting

confidence: 81%

Section: Subjectsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunctions(PSSD): Clinical Experience with a Multimodal Approach

Reisman¹,

Jannini²,

Jannini³

2022

JOMH

Self Cite

View full text Add to dashboard Cite

show abstract

“…Depending on the various drugs, the incidence of ED may range from 25.8 to 80.3% (14). Unfortunately, ED may persist after SSRIs are discontinued, with this treacherous condition being only recently defined as post-SSRI sexual dysfunction (PSSD) (29,30).…”

Section: Discussionmentioning

confidence: 99%

A Prospectively Validated Nomogram for Predicting the Risk of PHQ-9 Score ≥15 in Patients With Erectile Dysfunction: A Multi-Center Study

Zheng

Gao

Hou

et al. 2022

Front. Public Health

Self Cite

View full text Add to dashboard Cite

BackgroundAlthough erectile dysfunction (ED) often occurs simultaneously with depression, not all patients with ED suffer major depression (MD), with a PHQ-9 score ≥15 indicating MD. Because the PHQ-9 questionnaire includes phrases such as “I think I am a loser” and “I want to commit suicide,” the psychological burdens of ED patients are likely to increase inevitably after using the PHQ-9, which, in turn, may affect ED therapeutic effects. Accordingly, we endeavored to develop a nomogram to predict individual risk of PHQ-9 score ≥15 in these patients.MethodsThe data of 1,142 patients with ED diagnosed in Xijing Hospital and Northwest Women and Children's Hospital from January 2017 to May 2020 were analyzed. While the Least Absolute Shrinkage and Selection Operator regression was employed to screen PHQ-9 score ≥15 related risk factors, multivariate logistic regression analysis was performed to verify these factors and construct the nomogram. The training cohort and an independent cohort that comprised 877 prospectively enrolled patients were used to demonstrate the efficacy of the nomogram.ResultsThe IIEF-5 score, PEDT score, physical pain score, frequent urination, and feeling of endless urination were found to be independent factors of PHQ-9 score ≥15 in patients with ED. The nomogram developed by these five factors showed good calibration and discrimination in internal and external validation, with a predictive accuracy of 0.757 and 0.722, respectively. The sensitivity and specificity of the nomogram in the training cohort were 0.86 and 0.52, respectively. Besides, the sensitivity and specificity of the nomogram in the validation cohort were 0.73 and 0.62, respectively. Moreover, based on the nomogram, the sample was divided into low-risk and high-risk groups.ConclusionThis study established a nomogram to predict individual risk of PHQ-9 score ≥15 in patients with ED. It is deemed that the nomogram may be employed initially to avoid those with a low risk of MD completing questionnaires unnecessarily.

show abstract

“…It is noteworthy that SD may persist for a long time after the drug has been withdrawn. The so-called post-SSRI syndrome is considered a new challenge because, to date, no specific treatment exists and diagnostic criteria are far from being accepted by the academic world [ 15 ]. All these issues should be addressed when counselling and treating patients with epilepsy and depressive symptoms.…”

mentioning

confidence: 99%

Drug-Induced Sexual Dysfunction in Individuals with Epilepsy: Beyond Antiepileptic Compounds

Calabrò

Cerasa

2022

Medicines

Self Cite

View full text Add to dashboard Cite

show abstract

Diagnostic criteria for enduring sexual dysfunction after treatment with antidepressants, finasteride and isotretinoin

Cited by 25 publications

References 39 publications

Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunctions(PSSD): Clinical Experience with a Multimodal Approach

Post-Selective Serotonin Reuptake Inhibitor Sexual Dysfunctions(PSSD): Clinical Experience with a Multimodal Approach

A Prospectively Validated Nomogram for Predicting the Risk of PHQ-9 Score ≥15 in Patients With Erectile Dysfunction: A Multi-Center Study

Drug-Induced Sexual Dysfunction in Individuals with Epilepsy: Beyond Antiepileptic Compounds

Contact Info

Product

Resources

About